The markets on June 28, 2019 opened up. BSE Sensex is trading at 39,469.85, down by 116.56 points and the Nifty is trading at 11,804.25, down by 37.30 points. 

Like we check the financial ratios of the company to understand its financial health before purchasing stocks, we can check our own personal finance ratios to understand our overall financial health. So, what are these personal finance ratios, let’s find out.

Credit rating agency has downgraded the rating of Rohtak-Hissar Tollway Private Limited which is a wholly-owned subsidiary of Sadbhav Infrastructure. The rating was downgraded to CARE D from CARE BB+. Reacting to this development, the company’s stock fell by 5.63 per cent.

The company reported that it has defaulted payment towards maturity of its Unsecured Commercial Paper on June 26, 2019. For the Unsecured Commercial Paper aggregating to Rs. 200 crore, Rs. 50 crore was repaid and the balance amount of Rs. 150 crore has not been paid.

Overall volumes in futures & options currently stand at 3,90,04,211 contracts with a turnover of Rs.26,55,699.80 crore.

Overall volumes in futures & options currently stand at 3,90,04,211 contracts with a turnover of Rs.26,55,699.80 crore.

The level of 20-DMA (11,851) should be closely watched by the traders. Only a sustainable move above the 20-DMA is likely to take the Nifty towards the 12,000 mark, while on the downside, the level of 11,800, followed by 11,740, is likely to act as support. Stocks for news: Infosys, Cox & Kings, Excel Industries, MMTC, Lupin.

After witnessing high volatility in the second half of the trading session on the eve of June month expiry, Indian markets are expected to kick-off July series on a tepid note following mostly negative cues from the Asian peers.

The shares of Axis Bank sank more than 2 per cent from the day’s high of Rs. 806.65 during Thursday’s trading session. This could be because the bank is mulling over raising funds to the tune of at least US$1.3 billion by means of a share sale to institutional investors.

Lupin Limited (Lupin) on Thursday announced that it has received tentative approval from United States Food and Drug Administration (USFDA) for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg.